Indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa.
ORAL As monotherapy in Parkinson’s disease: Adult: Per tab contains L-dopa 100 mg & carbidopa 25 mg. Initially, 1 tab tid. Increase by 1 tab/day every 1-2 days up to a max. of 8 tabs of any strength! day. If the patient has been taking L-dopa alone, the combination should be started after a gap of at least 8 hr after stopping L-dopa.
Lactation, narrow angle glaucoma. melanoma, psychosis, severely decompensated endocrine. Heart disease, liver disease, dementia, psychosis, pregnancy, elderly, heart disease. Regular monitoring of renal & hepatic function is reccomended.
Nausea, vomiting, anorexia, increased risk of GI bleeding in peptic ulcer patients. Orthostatic hypotension, cardiac arrhythmias. Psychiatric symptoms (depression w/ or w/o suicidal tendency). Abnormal involuntary movements or dyskinesias, delirium, hallucinations (elderly). Slight elevation of liver enzymes, leucopenia & thrombocytopen ia. Severe postural hypotension in elderly.
There are no controlled data in human pregnancy. Two reports have described three patients who received levodopa or levodopa-carbidopa throughout pregnancy without evidence of fetal harm. Levodopa should only be given in human pregnancy when benefit outweighs risk. This drug in relatively low doses was used without apparent harmful effects in the nursing infant by 1 mother with Parkinson's disease; limited data indicate this drug is poorly excreted into breast milk.
.png&w=384&q=75)